Nursing Elites

1. A healthcare provider is planning to administer IV Alteplase to a client who is demonstrating manifestations of a massive Pulmonary Embolism. Which of the following interventions should the healthcare provider plan to take?

• A. Administer IM Enoxaparin along with the Alteplase dose.
• B. Hold direct pressure on puncture sites for up to 30 minutes.
• C. Administer Aminocaproic acid IV prior to alteplase infusion.
• D. Prepare to administer Alteplase within 8 hours of manifestation onset.

Correct answer: B

Rationale: When administering IV Alteplase for a massive Pulmonary Embolism, the healthcare provider should plan to hold direct pressure on puncture sites for 10 to 30 minutes or until oozing of blood stops. This is crucial to prevent bleeding complications at the puncture sites. Choice A is incorrect because Enoxaparin is not usually administered along with Alteplase for a Pulmonary Embolism. Choice C is incorrect because Aminocaproic acid is not typically given prior to alteplase infusion in this situation. Choice D is incorrect because Alteplase should be administered within 2 hours of onset of manifestations for Pulmonary Embolism, not within 8 hours.

2. A client has a prescription for a Nicotine transdermal patch. Which of the following instructions should the nurse include?

• A. Apply the patch at the same time each day.
• B. Remove the patch at bedtime.
• C. Apply the patch to the same location daily.
• D. Place the patch over an area of the body with hair.

Correct answer: A

Rationale: The correct instruction for a client using a Nicotine transdermal patch is to apply the patch at the same time each day. This helps maintain consistent blood levels of nicotine throughout the treatment period, which can aid in reducing cravings for smoking. Consistency in the application time is essential for the effectiveness of the patch. Choices B, C, and D are incorrect. Removing the patch at bedtime may disrupt the continuous delivery of nicotine, applying the patch to the same location daily can cause skin irritation, and placing the patch over an area with hair may affect its adhesion and absorption.

3. Which drug undergoes extensive first-pass hepatic metabolism?

• A. Heparin
• B. Insulin
• C. Propranolol
• D. Nitroglycerin

Correct answer: C

Rationale: Propranolol undergoes extensive first-pass hepatic metabolism in the liver. When administered orally, propranolol is extensively metabolized by the liver before reaching systemic circulation, leading to reduced bioavailability. This process is known as first-pass hepatic metabolism, which significantly affects the drug's effectiveness and necessitates higher oral doses compared to other routes of administration. Heparin (Choice A) is not metabolized by the liver but excreted unchanged by the kidneys. Insulin (Choice B) is a peptide hormone that is not subject to significant first-pass metabolism. Nitroglycerin (Choice D) is primarily metabolized in the blood and tissues, bypassing significant first-pass metabolism in the liver.

4. What is the expected pharmacological action of propranolol?

• A. Block stimulation of beta1 receptors
• B. Alter water and electrolyte transport in the large intestine
• C. Block stimulation of beta2 receptors
• D. Both A and C are correct

Correct answer: D

Rationale: Propranolol exerts its pharmacological action by blocking stimulation of both beta1 and beta2 receptors. By doing so, it leads to decreased heart rate and blood pressure. Therefore, both options A and C are correct as propranolol affects both types of beta receptors. Choice B is incorrect as propranolol does not alter water and electrolyte transport in the large intestine.

5. Which of the following drugs is associated with the reaction of tendon dysfunction?

• A. Digitalis
• B. Niacin
• C. Tetracycline
• D. Fluoroquinolones

Correct answer: D

Rationale: Fluoroquinolones are known to be associated with tendon dysfunction or rupture. These drugs can weaken the tendons, leading to potential issues such as tendonitis or even tendon rupture. It is essential for healthcare providers to be cautious when prescribing fluoroquinolones, especially in patients who may be at higher risk for tendon-related complications.

Similar Questions